Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 

Innovative Health Care Portfolio, 4  Ticker: FFGEOX
 
Description
A unit investment trust that seeks above-average capital appreciation. The portfolio provides access to health care companies that are involved in the areas that we believe are driving innovation.
Please note that there is no assurance the objective will be met.
 
Summary
Product Code: INHC4
Portfolio Status: Secondary
Initial Offer Date: 05/08/2020
Secondary Date: 08/05/2020
Portfolio Ending Date: 08/09/2021
Tax Structure: Regulated Investment Company
Distributions: Semi-Annual
 
Initial Offer Price: $10.0000
NAV(*): $10.6385
POP(*): $10.7841
Remaining Deferred Sales Charge: $0.1350
* As of Trade Date: 08/13/2020 4:00pm ET
The Public Offering Price (POP) represents the net asset value per unit plus any applicable organization costs and sales charges. The Net Asset Value (NAV) represents the value per unit of a trust’s portfolio securities and other assets reduced by applicable deferred sales charges and other liabilities.

 Historical 12-Month Distribution of Trust Holdings:^
Rate (as of 8/13/2020) Per Unit (as of 8/10/2020)
0.19% $0.02020
^ There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The historical 12-month distribution per unit and historical 12-month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's distribution or distribution rate. Due to the negative economic impact across many industries caused by the recent COVID-19 outbreak, certain issuers of the securities included in the trust may elect to reduce the amount of dividends and/or distributions paid in the future. As a result, the "Historical 12-Month Distribution Rate of Trust Holdings," which is based on the trailing twelve-month distributions paid by the securities included in a trust, will likely be higher, and in some cases significantly higher, than the actual distribution rate achieved by the trust. The historical 12-month distribution per unit is based on the weighted average of the trailing twelve month distributions paid by the securities included in the portfolio. The historical 12-month distribution rate is calculated by dividing the historical 12-month distributions by the trust's offering price. The historical 12-month distribution and rate are reduced to account for the effects of fees and expenses, which will be incurred when investing in a trust. Certain of the issuers may have reduced their dividends or distributions over the prior twelve months. The distribution per unit and rate paid by the trust may be higher or lower than the amount shown above due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, or the sale of securities in the portfolio. For trusts that include funds, distributions may include realized short term capital gains, realized long-term capital gains and/or return of capital. PLEASE NOTE: For trusts that hold preferred securities, the historical distribution rate is calculated using only the holdings that have 12 months of distribution history. Any holdings without a 12 month history of dividends were excluded from the calculation.

 Holdings Analysis Click here to Perform a Benchmark Comparison  
 Sector Weighting
Communication Services  Communication Services 0.00%
Consumer Discretionary  Consumer Discretionary 0.00%
Consumer Staples  Consumer Staples 0.00%
Energy  Energy 0.00%
Financials  Financials 0.00%
Health Care  Health Care 99.97%
Industrials  Industrials 0.00%
Information Technology  Information Technology 0.00%
Materials  Materials 0.00%
Real Estate  Real Estate 0.00%
Utilities  Utilities 0.00%
Other  Other 0.03%
 
  Large Mid Small  
Growth  31.15% 32.41% 9.38%  
Value  27.03% 0.00% 0.00%  

 Style Weighting
Large-Cap Growth 31.15%
Large-Cap Value 27.03%
Mid-Cap Growth 32.41%
Mid-Cap Value 0.00%
Small-Cap Growth 9.38%
Small-Cap Value 0.00%
Undetermined 0.03%
 Composition
U.S. Stocks 89.08%   Other 0.03%
Non-U.S. Stocks 10.89%      
The style and sector characteristics of the portfolio are determined as of 08/12/2020 and will likely vary thereafter due to market fluctuations in the underlying securities.  

 Key Stats
Weighted Average Market Cap $47,131.16
Price/Book 5.99
As of 8/12/2020
All market capitalization numbers are in USD$ Millions

 Holdings  Export Current Holdings | View Initial Holdings  
NameSymbolSectorStyleWeighting
 CRISPR Therapeutics AG CRSP Health Care  Health Care Mid-Cap Growth 3.88%
 Mirati Therapeutics, Inc. MRTX Health Care  Health Care Mid-Cap Growth 3.24%
 Ultragenyx Pharmaceutical Inc. RARE Health Care  Health Care Mid-Cap Growth 3.04%
 Veeva Systems Inc. (Class A) VEEV Health Care  Health Care Large-Cap Growth 3.01%
 Moderna, Inc. MRNA Health Care  Health Care Large-Cap Growth 2.99%
 Intuitive Surgical, Inc. ISRG Health Care  Health Care Large-Cap Growth 2.94%
 Zoetis Inc. ZTS Health Care  Health Care Large-Cap Growth 2.94%
 Sarepta Therapeutics, Inc. SRPT Health Care  Health Care Mid-Cap Growth 2.92%
 BioMarin Pharmaceutical Inc. BMRN Health Care  Health Care Large-Cap Growth 2.90%
 Koninklijke Philips N.V. (NY Shares) PHG Health Care  Health Care Large-Cap Value 2.88%
 Thermo Fisher Scientific Inc. TMO Health Care  Health Care Large-Cap Value 2.82%
 Halozyme Therapeutics, Inc. HALO Health Care  Health Care Mid-Cap Growth 2.79%
 IQVIA Holdings Inc. IQV Health Care  Health Care Large-Cap Value 2.71%
 Zimmer Biomet Holdings, Inc. ZBH Health Care  Health Care Large-Cap Value 2.64%
 Repligen Corporation RGEN Health Care  Health Care Mid-Cap Growth 2.64%
 Globus Medical, Inc. (Class A) GMED Health Care  Health Care Mid-Cap Growth 2.60%
 Illumina, Inc. ILMN Health Care  Health Care Large-Cap Growth 2.54%
 Cerner Corporation CERN Health Care  Health Care Large-Cap Value 2.46%
 Alexion Pharmaceuticals, Inc. ALXN Health Care  Health Care Large-Cap Value 2.40%
 Bristol-Myers Squibb Company BMY Health Care  Health Care Large-Cap Value 2.39%
 Teladoc Health, Inc. TDOC Health Care  Health Care Mid-Cap Growth 2.39%
 Amgen Inc. AMGN Health Care  Health Care Large-Cap Growth 2.38%
 DexCom, Inc. DXCM Health Care  Health Care Large-Cap Growth 2.37%
 HealthEquity, Inc. HQY Health Care  Health Care Mid-Cap Growth 2.37%
 Vertex Pharmaceuticals Incorporated VRTX Health Care  Health Care Large-Cap Growth 2.33%
 Medtronic Plc MDT Health Care  Health Care Large-Cap Value 2.32%
 PTC Therapeutics, Inc. PTCT Health Care  Health Care Small-Cap Growth 2.31%
 Johnson & Johnson JNJ Health Care  Health Care Large-Cap Growth 2.30%
 Bio-Techne Corporation TECH Health Care  Health Care Mid-Cap Growth 2.27%
 Seattle Genetics, Inc. SGEN Health Care  Health Care Large-Cap Growth 2.25%
 Stryker Corporation SYK Health Care  Health Care Large-Cap Value 2.22%
 Incyte Corporation INCY Health Care  Health Care Large-Cap Growth 2.20%
 Alnylam Pharmaceuticals, Inc. ALNY Health Care  Health Care Mid-Cap Growth 2.19%
 Biogen Inc. BIIB Health Care  Health Care Large-Cap Value 2.16%
 Masimo Corporation MASI Health Care  Health Care Mid-Cap Growth 2.08%
 NuVasive, Inc. NUVA Health Care  Health Care Small-Cap Growth 2.05%
 Gilead Sciences, Inc. GILD Health Care  Health Care Large-Cap Value 2.03%
 Zymeworks Inc. ZYME Health Care  Health Care Small-Cap Growth 1.81%
 Tabula Rasa HealthCare, Inc. TRHC Health Care  Health Care Small-Cap Growth 1.76%
 Intercept Pharmaceuticals, Inc. ICPT Health Care  Health Care Small-Cap Growth 1.45%
 
Total Number of Holdings:    40
Underlying Securities information represented above is as of 08/12/2020 but will vary with future fluctuations in the market.

 Deferred Sales Charge Schedule
Amount Date
$0.04500 August 20, 2020
$0.04500 September 18, 2020
$0.04500 October 20, 2020

Risk Considerations

Closed-End Fund and ETF Risk. Closed-end funds and ETFs are subject to various risks, including management's ability to meet the fund's investment objective, and to manage the fund's portfolio when the underlying securities are redeemed or sold, during periods of market turmoil and as investors' perceptions regarding ETFs, closed-end funds or their underlying investments change. Unlike open-end funds, which trade at prices based on a current determination of the fund's net asset value, ETFs and closed-end funds frequently trade at a discount from their net asset value in the secondary market. Certain closed-end funds in which the portfolio invests may employ the use of leverage, which increases the volatility of such funds.

Closed-End Fund Risk. Closed-end funds are subject to various risks, including management's ability to meet the fund's investment objective, and to manage the fund's portfolio when the underlying securities are redeemed or sold, during periods of market turmoil and as investors' perceptions regarding the funds or their underlying investments change. Unlike open-end funds, which trade at prices based on a current determination of the fund's net asset value, closed-end funds frequently trade at a discount to their net asset value in the secondary market. Certain closed-end funds employ the use of leverage, which increases the volatility of such funds.

COVID-19 Economic Impact Risk. The recent outbreak of a respiratory disease designated as COVID-19 was first detected in China in December 2019. The global economic impact of the COVID-19 outbreak is impossible to predict but is expected to disrupt manufacturing, supply chains and sales in affected areas and negatively impact global economic growth prospects. The COVID-19 outbreak has also caused significant volatility and declines in global financial markets, which have caused losses for investors. The impact of the COVID-19 outbreak may be short term or may last for an extended period of time, and in either case could result in a substantial economic downturn or recession.

Health Care Risk. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

Large-Cap Risk. Large capitalization companies may grow at a slower rate than the overall market.

Additional Risk. For a discussion of additional risks of investing in the trust see the "Risk Factors" section of the prospectus.

Important Note. It is important to note that an investment can be made in the underlying funds directly rather than through the trust. These direct investments can be made without paying the trust's sales charge, operating expenses and organizational costs.

Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

The style and capitalization characteristics used to describe the stocks are designed to help you understand how they fit into your overall investment plan. Due to changes in the value of the stocks the characteristics may vary over time. In general, growth stocks have high relative price-to-book ratios while value stocks have low relative price-to-book ratios. In determining market capitalization characteristics, we analyze the market capitalizations of the 3,000 largest stocks in the U.S. (excluding foreign securities, ADRs, limited partnerships and regulated investment companies) on a monthly basis. Companies with market capitalizations among the largest 10% are considered Large-Cap securities, the next 20% are considered Mid-Cap securities and the remaining securities are considered Small-Cap securities.

You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

Fund Cusip Information
30313Y187 (Cash)
30313Y195 (Reinvest)
30313Y203 (Cash-Fee)
30313Y211 (Reinvest-Fee)
Printer Friendly Page Printer Friendly Page

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2020 All rights reserved.